CA2969619A1 - Guide rna with chemical modifications - Google Patents

Guide rna with chemical modifications Download PDF

Info

Publication number
CA2969619A1
CA2969619A1 CA2969619A CA2969619A CA2969619A1 CA 2969619 A1 CA2969619 A1 CA 2969619A1 CA 2969619 A CA2969619 A CA 2969619A CA 2969619 A CA2969619 A CA 2969619A CA 2969619 A1 CA2969619 A1 CA 2969619A1
Authority
CA
Canada
Prior art keywords
certain embodiments
guide rna
modification
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2969619A
Other languages
English (en)
French (fr)
Inventor
Daniel E. Ryan
Douglas J. Dellinger
Jeffrey R. Sampson
Robert Kaiser
Joel Myerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agilent Technologies Inc
Original Assignee
Agilent Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2969619(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agilent Technologies Inc filed Critical Agilent Technologies Inc
Publication of CA2969619A1 publication Critical patent/CA2969619A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2969619A 2014-12-03 2015-12-03 Guide rna with chemical modifications Pending CA2969619A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462087211P 2014-12-03 2014-12-03
US62/087,211 2014-12-03
US201562146189P 2015-04-10 2015-04-10
US62/146,189 2015-04-10
US201562256095P 2015-11-16 2015-11-16
US62/256,095 2015-11-16
PCT/US2015/000143 WO2016089433A1 (en) 2014-12-03 2015-12-03 Guide rna with chemical modifications

Publications (1)

Publication Number Publication Date
CA2969619A1 true CA2969619A1 (en) 2016-06-09

Family

ID=56092183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2969619A Pending CA2969619A1 (en) 2014-12-03 2015-12-03 Guide rna with chemical modifications

Country Status (8)

Country Link
US (5) US10900034B2 (enExample)
EP (2) EP4400584A3 (enExample)
JP (2) JP7068821B2 (enExample)
KR (2) KR102629128B1 (enExample)
CN (1) CN107250148B (enExample)
AU (1) AU2015355546B2 (enExample)
CA (1) CA2969619A1 (enExample)
WO (1) WO2016089433A1 (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
MX375420B (es) 2014-02-11 2025-03-06 Univ Colorado Regents Ingenieria genetica multiplexada habilitada por crispr.
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
JP6718872B2 (ja) 2014-12-17 2020-07-08 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップＰｒｏＱＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＩＩ Ｂ．Ｖ． 標的化ｒｎａ編集
JP2017538427A (ja) 2014-12-18 2017-12-28 インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド Ｃｒｉｓｐｒ系組成物及び使用方法
BR112017017812A2 (pt) 2015-02-23 2018-04-10 Crispr Therapeutics Ag materiais e métodos para tratamento de hemoglobinopatias
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
CN114231527A (zh) 2015-04-06 2022-03-25 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
US11279928B2 (en) 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
AU2016285724A1 (en) * 2015-06-29 2017-11-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
EP3159407A1 (en) * 2015-10-23 2017-04-26 Silence Therapeutics (London) Ltd Guide rnas, methods and uses
WO2017077394A2 (en) 2015-11-04 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2017136794A1 (en) * 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US10767175B2 (en) * 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
JP7074345B2 (ja) 2016-06-22 2022-05-24 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 一本鎖ｒｎａ編集オリゴヌクレオチド
JP2019518478A (ja) 2016-06-24 2019-07-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ バーコードを付けたコンビナトリアルライブラリーを生成する方法
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
EP3500671B1 (en) * 2016-08-17 2024-07-10 The Broad Institute, Inc. Method of selecting target sequences for the design of guide rnas
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
IL264923B2 (en) 2016-09-01 2025-07-01 Proqr Therapeutics Ii Bv Single-stranded RNA-editing oligonucleotides with chemical modifications
US11306305B2 (en) 2016-09-23 2022-04-19 Board Of Trustees Of Southern Illinois University Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
EP3516061A1 (en) 2016-09-23 2019-07-31 Synthena AG Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
WO2018055577A1 (en) * 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
US10669539B2 (en) * 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
EP3523427A4 (en) 2016-10-07 2020-09-02 Integrated DNA Technologies, Inc. S. PYOGENES AND POLYPEPTIDES MUTANT CAS9 GENES CODED BY SUCH GENES
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
US11732258B2 (en) 2016-11-02 2023-08-22 President And Fellows Of Harvard College Engineered guide RNA sequences for in situ detection and sequencing
EP3541945A4 (en) * 2016-11-18 2020-12-09 Genedit Inc. COMPOSITIONS AND METHODS OF MODIFICATION OF TARGET NUCLEIC ACIDS
WO2018098383A1 (en) 2016-11-22 2018-05-31 Integrated Dna Technologies, Inc. Crispr/cpf1 systems and methods
CN119464289A (zh) 2016-12-08 2025-02-18 因特利亚治疗公司 经修饰的指导rna
WO2018111947A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing enhancement
WO2018118587A1 (en) * 2016-12-22 2018-06-28 Agenovir Corporation Modified polynucleotides for antiviral therapy
KR102551664B1 (ko) 2016-12-22 2023-07-05 인텔리아 테라퓨틱스, 인크. 알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US20190382751A1 (en) * 2016-12-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modified crispr rna and uses thereof
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
JP7386082B2 (ja) 2017-02-28 2023-11-24 ブイオーアール バイオファーマ インコーポレーテッド 系統特異的タンパク質の阻害のための組成物および方法
US20180258485A1 (en) * 2017-03-07 2018-09-13 The Regents Of The University Of Colorado, A Body Corporate Boranephosphonate Detection Probes and Methods For Producing and Using the Same
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
EP3601568A1 (en) 2017-03-31 2020-02-05 Agenovir Corporation Antiviral therapeutic
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
GB2582865B (en) * 2017-09-11 2022-05-04 Synthego Corp Biopolymer synthesis system and method
CN111373044B (zh) 2017-09-19 2025-01-28 热带生物科学英国有限公司 修饰用于沉默基因表达的植物非编码rna分子的特异性的方法
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2019084664A1 (en) * 2017-11-02 2019-05-09 The Governors Of The University Of Alberta Chemically-modified guide rnas to improve crispr-cas protein specificity
CN111629747A (zh) 2017-12-05 2020-09-04 沃泰克斯药物股份有限公司 Crispr-cas9修饰的cd34+人血色素干细胞和祖细胞及其用途
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11268092B2 (en) 2018-01-12 2022-03-08 GenEdit, Inc. Structure-engineered guide RNA
WO2019147743A1 (en) * 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
EP3749767A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
MA51788A (fr) 2018-02-05 2020-12-16 Vertex Pharma Substances et méthodes pour traiter des hémoglobinopathies
CN110573184B (zh) 2018-02-09 2025-05-13 俄亥俄州立创新基金会 Rna纳米结构，其制备方法和用途
CA3093702A1 (en) * 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2019183000A1 (en) * 2018-03-19 2019-09-26 University Of Massachusetts Modified guide rnas for crispr genome editing
EP3768328A4 (en) * 2018-03-23 2021-12-22 Refuge Biotechnologies, Inc. GENE REGULATION THROUGH CONDITIONAL NUCLEAR LOCALIZATION OF GENE-MODULATING POLYPEPTIDES
US12378549B2 (en) 2018-05-11 2025-08-05 UNIVERSITé LAVAL CRISPR-cas9 system and uses thereof
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2019224603A1 (en) * 2018-05-24 2019-11-28 Crispr Therapeutics Ag Methods and compositions for efficient gene deletion
CN112567036A (zh) * 2018-06-08 2021-03-26 因特利亚治疗公司 用于基因编辑的修饰的向导rna
EP4159872B1 (en) * 2018-06-25 2024-09-11 Bionano Genomics, Inc. Labeling of dna
US12338436B2 (en) 2018-06-29 2025-06-24 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
US20220195403A1 (en) * 2018-07-13 2022-06-23 Allele Biotechnology And Pharmaceuticals, Inc. Methods of achieving high specificity of genome editing
JP2022520138A (ja) 2018-08-28 2022-03-29 ブイオーアール バイオファーマ インコーポレーテッド 遺伝子操作された造血幹細胞およびそれらの使用
US20210310002A1 (en) * 2018-08-31 2021-10-07 City Of Hope Cationic compounds for delivery of nucleic acids
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
JP7553100B2 (ja) * 2018-12-12 2024-09-18 国立大学法人九州大学 ゲノム編集された細胞の製造方法
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201901873D0 (en) * 2019-02-11 2019-04-03 Proqr Therapeutics Ii Bv Antisense oligonucleotides for nucleic acid editing
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3962535A1 (en) 2019-04-30 2022-03-09 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
US20220228153A1 (en) 2019-05-23 2022-07-21 Vor Biopharma Inc. Compositions and methods for cd33 modification
WO2020247882A1 (en) 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Engineered casx systems
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CN113677793A (zh) * 2019-07-19 2021-11-19 辛瑟高公司 稳定的crispr复合物
JP7630904B2 (ja) * 2019-07-23 2025-02-18 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
JP2022546505A (ja) 2019-08-28 2022-11-04 ブイオーアール バイオファーマ インコーポレーテッド Ｃｄ１２３改変ための組成物および方法
KR20220047380A (ko) 2019-08-28 2022-04-15 보르 바이오파마 인크. Cll1 변형을 위한 조성물 및 방법
AU2020348860A1 (en) * 2019-09-19 2022-04-07 Modernatx, Inc. Cap guides and methods of use thereof for RNA mapping
EP4038190A1 (en) 2019-10-03 2022-08-10 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021070494A1 (ja) 2019-10-11 2021-04-15 住友化学株式会社 核酸オリゴマーの製造方法
CN114746125B (zh) 2019-11-08 2025-08-08 瑞泽恩制药公司 用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略
EP4028521A1 (en) * 2019-12-09 2022-07-20 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
AU2020401206A1 (en) * 2019-12-11 2022-07-14 Intellia Therapeutics, Inc. Modified guide RNAs for gene editing
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
WO2021153770A1 (en) 2020-01-29 2021-08-05 Sumitomo Chemical Company, Limited Process of preparing nucleic acid oligomer
KR20220133878A (ko) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
WO2021193954A1 (ja) 2020-03-27 2021-09-30 住友化学株式会社 核酸オリゴマーの製造方法
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
MX2023001028A (es) 2020-07-24 2023-04-24 Massachusetts Gen Hospital Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas.
WO2022047165A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cd123 modification
JP2023540276A (ja) 2020-08-28 2023-09-22 ブイオーアール バイオファーマ インコーポレーテッド Ｃｌｌ１改変のための組成物および方法
US20230398219A1 (en) 2020-09-14 2023-12-14 Vor Biopharma Inc. Compositions and methods for cd38 modification
WO2022056459A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
US20240033290A1 (en) 2020-09-18 2024-02-01 Vor Biopharma Inc. Compositions and methods for cd7 modification
US20230323405A1 (en) 2020-09-18 2023-10-12 Artisan Development Labs, Inc. Constructs and uses thereof for efficient and specific genome editing
WO2022064908A1 (ja) 2020-09-24 2022-03-31 住友化学株式会社 核酸オリゴマーの製造方法
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
US20230364146A1 (en) 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022075816A1 (ko) * 2020-10-08 2022-04-14 주식회사 진코어 Crispr/cas12f1(cas14a1) 시스템 효율화를 위한 엔지니어링 된 가이드 rna 및 이의 용도
WO2022093983A1 (en) 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
CA3201003A1 (en) 2020-11-13 2022-05-19 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
CN112266951B (zh) * 2020-11-23 2021-07-20 广东省农业科学院植物保护研究所 一种生物素标记引物延伸方法及其应用
WO2022115878A1 (en) * 2020-11-30 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas-mediated gene editing of human stem cells
JP2023552374A (ja) 2020-12-03 2023-12-15 スクライブ・セラピューティクス・インコーポレイテッド 操作されたクラス２ ｖ型ｃｒｉｓｐｒシステム
CN116724109A (zh) 2020-12-31 2023-09-08 Vor生物制药股份有限公司 用于cd34基因修饰的组合物和方法
WO2022182801A1 (en) 2021-02-25 2022-09-01 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
US20240200059A1 (en) 2021-04-09 2024-06-20 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
CN113512767B (zh) * 2021-04-30 2022-09-23 天津诺禾致源生物信息科技有限公司 用于构建small RNA文库的接头、试剂盒及small RNA文库的构建方法
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022266139A2 (en) 2021-06-14 2022-12-22 Graphite Bio, Inc. Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
US20250034558A1 (en) 2021-06-18 2025-01-30 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
EP4367504A4 (en) * 2021-07-02 2025-06-18 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone KINETIC BARCODING TO IMPROVE THE SPECIFICITY OF CRISPR/CAS REACTIONS
US20240384304A1 (en) 2021-07-06 2024-11-21 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
WO2023283495A1 (en) * 2021-07-09 2023-01-12 The Brigham And Women's Hospital, Inc. Crispr-based protein barcoding and surface assembly
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
JP2024538489A (ja) 2021-09-03 2024-10-23 キュアバック エスイー 核酸を送達するための新規な脂質ナノ粒子
CA3230927A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023043856A1 (en) * 2021-09-14 2023-03-23 Agilent Technologies, Inc. Methods for using guide rnas with chemical modifications
WO2023049926A2 (en) 2021-09-27 2023-03-30 Vor Biopharma Inc. Fusion polypeptides for genetic editing and methods of use thereof
EP4410770A1 (en) 2021-09-28 2024-08-07 Sumitomo Chemical Company, Limited Production method for purified dichloroacetic acid
KR20240114295A (ko) * 2021-11-03 2024-07-23 인텔리아 테라퓨틱스, 인크. 유전자 편집을 위한 변형된 가이드 rna
EP4430186A1 (en) 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
EP4453245A4 (en) * 2021-12-23 2025-12-31 Mammoth Biosciences Inc DOSING IMPROVEMENTS BASED ON A PROGRAMMABLE NUCLEASE
WO2023164636A1 (en) 2022-02-25 2023-08-31 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
US20250388896A1 (en) 2022-03-01 2025-12-25 Celyntra Therapeutics Sa Composition and methods for transgene insertion
WO2023182274A1 (ja) 2022-03-23 2023-09-28 住友化学株式会社 核酸オリゴマーの製造方法
EP4499829A2 (en) 2022-03-29 2025-02-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
EP4504771A1 (en) 2022-04-04 2025-02-12 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
US20250308637A1 (en) 2022-05-20 2025-10-02 Celyntra Therapeutics Sa Systems and methods for assessing risk of genome editing events
EP4555091A2 (en) 2022-07-13 2025-05-21 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
JPWO2024019137A1 (enExample) 2022-07-22 2024-01-25
EP4563559A1 (en) 2022-07-28 2025-06-04 Sumitomo Chemical Company, Limited Thionizing solution
CN119948162A (zh) 2022-09-22 2025-05-06 锐正基因(苏州)有限公司 用于治疗高胆固醇血症和/或心血管疾病的组合物和方法
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
CN119948043A (zh) 2022-10-27 2025-05-06 住友化学株式会社 寡核苷酸的制造方法
JP2026502125A (ja) 2022-12-19 2026-01-21 カマウ セラピューティクス， インコーポレイテッド Ｐ５３結合タンパク質５３ｂｐ１の改良型ペプチド阻害剤
WO2024138131A1 (en) * 2022-12-22 2024-06-27 Trustees Of Tufts College Expanding applications of zgtc alphabet in protein expression and gene editing
WO2024140737A1 (en) * 2022-12-26 2024-07-04 Huidagene Therapeutics Co., Ltd. Modified guide rna and uses thereof
KR20250128304A (ko) 2022-12-26 2025-08-27 스미또모 가가꾸 가부시끼가이샤 올리고뉴클레오티드의 제조 방법
WO2024163787A1 (en) * 2023-02-01 2024-08-08 University Hospitals Cleveland Medical Center Crispr technologies for diagnostic applications
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
KR20250168601A (ko) * 2023-04-07 2025-12-02 제넨테크, 인크. 변형된 가이드 rna
AU2024261906A1 (en) * 2023-04-28 2025-10-23 Beam Therapeutics Inc. Modified guide rna
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025076141A1 (en) 2023-10-03 2025-04-10 Inari Agriculture Technology, Inc. Viral delivery of grna to the scion
WO2026020120A1 (en) * 2024-07-19 2026-01-22 University Of Massachusetts Increasing cas9 genome editing fidelity through attenuation of guide rna watson-crick base pairing potential

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US7371580B2 (en) 2001-08-24 2008-05-13 Agilent Technologies, Inc. Use of unstructured nucleic acids in assaying nucleic acid molecules
US20070122906A1 (en) 2003-12-29 2007-05-31 Allan Mishra Method of culturing cells
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
DK2476689T3 (en) 2007-05-10 2016-01-18 Agilent Technologies Inc Thiocarbonbeskyttende groups for RNA synthesis
US20100076183A1 (en) 2008-09-22 2010-03-25 Dellinger Douglas J Protected monomer and method of final deprotection for rna synthesis
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
KR101833589B1 (ko) 2012-02-24 2018-03-02 프레드 헛친슨 켄서 리서치 센터 이상혈색소증 치료를 위한 조성물 및 방법
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN110156844A (zh) 2012-05-21 2019-08-23 安捷伦科技有限公司 组合物和缀合寡核苷酸的方法
EP4570908A3 (en) * 2012-05-25 2025-10-22 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US20140075593A1 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fluorescence activated cell sorting (facs) enrichment to generate plants
EP3406715B1 (en) 2012-09-07 2023-12-13 Corteva Agriscience LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
CN116064532A (zh) 2012-10-23 2023-05-05 基因工具股份有限公司 用于切割靶dna的组合物及其用途
WO2014071235A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
AU2013337651B2 (en) 2012-11-01 2018-12-13 Factor Bioscience Inc. Methods and products for expressing proteins in cells
PT3401388T (pt) 2012-12-06 2019-08-29 Synthetic Genomics Inc Mutantes de algas com um fenótipo de aclimatação à luminosidade elevada bloqueado
SG11201503824SA (en) 2012-12-06 2015-06-29 Sigma Aldrich Co Llc Crispr-based genome modification and regulation
WO2014089513A1 (en) 2012-12-06 2014-06-12 Synthetic Genomics, Inc. Autonomous replication sequences and episomal dna molecules
PT2784162E (pt) 2012-12-12 2015-08-27 Broad Inst Inc Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK3064585T3 (da) 2012-12-12 2020-04-27 Broad Inst Inc Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
WO2014093595A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
WO2014159719A1 (en) 2013-03-14 2014-10-02 Scrips Health Methods of isolating nucleic acids
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
MX376838B (es) 2013-03-15 2025-03-07 Univ Minnesota Ingenieria genomica de plantas utilizando sistemas crispr/cas.
KR102405549B1 (ko) 2013-03-15 2022-06-08 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20160046959A1 (en) 2013-03-15 2016-02-18 Carlisle P. Landel Reproducible method for testis-mediated genetic modification (tgm) and sperm-mediated genetic modification (sgm)
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CN105518146B (zh) 2013-04-04 2022-07-15 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
EP2981612B1 (en) 2013-04-04 2019-07-03 Trustees of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
US20160040155A1 (en) 2013-04-16 2016-02-11 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
SMT202100516T1 (it) 2013-04-16 2021-11-12 Regeneron Pharma Modificazione mirata del genoma di ratto
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
JP7065564B2 (ja) 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
AU2014273085B2 (en) 2013-05-29 2020-10-22 Cellectis New compact scaffold of Cas9 in the type II CRISPR system
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
SG10201913068PA (en) 2013-06-04 2020-02-27 Harvard College Rna-guided transcriptional regulation
US20150315252A1 (en) 2013-06-11 2015-11-05 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
EP3008181B1 (en) 2013-06-11 2019-11-06 The Regents of The University of California Methods and compositions for target dna modification
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
AU2014281026B2 (en) 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
SG11201600059QA (en) 2013-07-09 2016-02-26 Harvard College Multiplex rna-guided genome engineering
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
US20160143256A1 (en) 2013-07-10 2016-05-26 Joseph A. MAJZOUB Mrap2 knockouts
WO2015006294A2 (en) 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
MX363842B (es) 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
KR20160048212A (ko) 2013-09-04 2016-05-03 씨에스아이알 유전자 발현을 침묵화시키기 위해 유전자 조절 인자들을 표적으로하는 부위-특이적인 뉴클레아제 단일 세포 분석법
US20150064149A1 (en) 2013-09-04 2015-03-05 Mice With Horns, LLC. Materials and methods for correcting recessive mutations in animals
EP4279496A3 (en) 2013-09-04 2024-03-13 Corteva Agriscience LLC Rapid targeting analysis in crops for determining donor insertion
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150071946A1 (en) 2013-09-06 2015-03-12 The Johns Hopkins University Tumor-specific retrotransposon insertions
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2015040075A1 (en) 2013-09-18 2015-03-26 Genome Research Limited Genomic screening methods using rna-guided endonucleases
TW201542816A (zh) 2013-09-18 2015-11-16 Kymab Ltd 方法、細胞與生物體
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
AU2014331939A1 (en) 2013-10-08 2016-04-28 Amelia HENRY Drought-resistant cereal grasses and related materials and methods
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
JP6649261B2 (ja) 2013-11-04 2020-02-19 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
EP3066192B1 (en) 2013-11-04 2019-05-01 Dow AgroSciences LLC A universal donor system for gene targeting
NZ735257A (en) 2013-11-04 2018-09-28 Dow Agrosciences Llc Optimal soybean loci
BR102014027438B1 (pt) 2013-11-04 2022-09-27 Dow Agrosciences Llc Molécula de ácido nucleico recombinante e método de produção de uma célula vegetal transgênica
JP6634022B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なダイズ遺伝子座
ES2670983T3 (es) 2013-11-07 2018-06-04 Editas Medicine, Inc. Métodos y composiciones relacionados con CRISPR con ARNg rectores
WO2015070062A1 (en) 2013-11-07 2015-05-14 Massachusetts Institute Of Technology Cell-based genomic recorded accumulative memory
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
WO2015075056A1 (en) 2013-11-19 2015-05-28 Thermo Fisher Scientific Baltics Uab Programmable enzymes for isolation of specific dna fragments
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CA2932478A1 (en) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
WO2015089277A1 (en) 2013-12-12 2015-06-18 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
WO2015089465A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
CA2932439A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
AU2015266770A1 (en) 2014-05-30 2016-12-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
US20150344836A1 (en) 2014-05-30 2015-12-03 Ohio State Innovation Foundation Agrobacterium Strains for Plant Transformation and Related Materials and Methods
CN106604994B (zh) 2014-06-23 2021-12-14 通用医疗公司 通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
MX379237B (es) 2014-06-23 2025-03-10 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
EP3164148A4 (en) 2014-06-25 2017-12-13 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US9970030B2 (en) 2014-08-27 2018-05-15 Caribou Biosciences, Inc. Methods for increasing CAS9-mediated engineering efficiency
EP3450558B1 (en) 2014-08-27 2020-09-30 New England Biolabs, Inc. Synthon formation
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
MX2017003932A (es) 2014-09-26 2017-06-30 Philip Morris Products Sa Reduccion de nitrosaminas especificas del tabaco mediante la alteracion de la via de asimilacion de nitrato.
EP3197270B1 (en) 2014-09-26 2025-12-03 Pioneer Hi-Bred International, Inc. Wheat ms1 polynucleotides, polypeptides, and methods of use
US20170349940A1 (en) 2014-09-26 2017-12-07 Two Pore Guys, Inc. Targeted Sequence Detection by Nanopore Sensing of Synthetic Probes
WO2016073079A2 (en) 2014-09-26 2016-05-12 Yale University Compositions and methods for biocontainment of microorganisms
US9879283B2 (en) 2014-10-09 2018-01-30 Life Technologies Corporation CRISPR oligonucleotides and gene editing
EP3204050A4 (en) 2014-10-09 2018-04-04 The Regents of The University of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
JP2017536096A (ja) 2014-10-09 2017-12-07 アントフロゲネシス コーポレーション 胎盤由来の接着細胞エクソソームおよびそれらの使用
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
WO2016070037A2 (en) 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
CN114231527A (zh) 2015-04-06 2022-03-25 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
DK3390632T3 (da) 2015-12-18 2025-12-01 Danisco Us Inc Fremgangsmåder og sammensætninger til polymerase ii (pol-ii)-baseret guide-rna-ekspression
CN109072218B (zh) 2015-12-18 2023-04-18 国立研究开发法人科学技术振兴机构 基因修饰非人生物、卵细胞、受精卵以及目的基因的修饰方法
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
DK3390631T3 (da) 2015-12-18 2020-07-13 Danisco Us Inc Fremgangsmåder og sammensætninger til t-rna-baseret guide-rna-ekspression
US11118194B2 (en) 2015-12-18 2021-09-14 The Regents Of The University Of California Modified site-directed modifying polypeptides and methods of use thereof

Also Published As

Publication number Publication date
KR102763527B1 (ko) 2025-02-05
EP4400584A3 (en) 2024-10-16
CN107250148A (zh) 2017-10-13
JP7068821B2 (ja) 2022-05-17
AU2015355546B2 (en) 2021-10-14
US20230416733A1 (en) 2023-12-28
AU2015355546A1 (en) 2017-07-13
JP2022078083A (ja) 2022-05-24
EP3227447A4 (en) 2018-07-11
EP4400584A2 (en) 2024-07-17
KR20170084334A (ko) 2017-07-19
EP3227447A1 (en) 2017-10-11
US20180051281A1 (en) 2018-02-22
CN107250148B (zh) 2021-04-16
US10337001B2 (en) 2019-07-02
US20160289675A1 (en) 2016-10-06
JP7579820B2 (ja) 2024-11-08
EP3227447B1 (en) 2024-04-24
JP2017537626A (ja) 2017-12-21
US20250092389A1 (en) 2025-03-20
WO2016089433A1 (en) 2016-06-09
US10900034B2 (en) 2021-01-26
KR102629128B1 (ko) 2024-01-25
KR20240013283A (ko) 2024-01-30
US20210079389A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US20250092389A1 (en) Guide rna with chemical modifications
JP7431891B2 (ja) 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集
AU2020259548B2 (en) Methods and compositions for editing RNAs
US10526590B2 (en) Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination
US20220033858A1 (en) Crispr oligoncleotides and gene editing
AU2016359629B2 (en) Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
CN113661242A (zh) 包含经修饰的环状多核糖核苷酸的组合物及其用途
Kupryushkin et al. Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells
Mikutis et al. Technologies for targeted RNA degradation and induced RNA decay
Mizu et al. Enhancement of the antisense effect of polysaccharide–polynucleotide complexes by preventing the antisense oligonucleotide from binding to proteins in the culture medium
Reza et al. Therapeutic genome mutagenesis using synthetic donor DNA and triplex-forming molecules
US20250388896A1 (en) Composition and methods for transgene insertion
Mazzotti Developing light-activated nucleic acids for gene knockdown in cell-free and living systems
Lyu et al. Synthesis of long and functionally active RNAs facilitated by acetal levulinic ester chemistry

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201

EEER Examination request

Effective date: 20201201